Immuron Q3 FY23 Business Update Presentation
April 19 2023 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company that has developed
two commercially available oral immunotherapeutic products for the
treatment of gut mediated diseases, is pleased to provide the Q3
FY23 Investor Presentation for the business update webinar to be
held
today at 11:00 am (AEST).
The Investor Presentation includes the following material
information (unaudited):
- Worldwide sales for the two weeks 1 to 14 April 2023 were
A$320,000. This represents 37% of sales for the whole of Q3 FY23 of
A$875,000.
- Sales FY23 YTD to 14 April 2023 of A$1,779,000 represents a
233% increase over the corresponding prior period YTD to 14 April
2022 of $534,000.
Investors are invited to join the webcast and
Q&A hosted by Immuron CEO Steven Lydeamore.
To register for the webinar, please click on
this link:
https://us02web.zoom.us/webinar/register/WN_TpvaXZZ1QDG1FnZdXdtSGA
After registering, you will receive a
confirmation email containing information to join the webinar.
A copy of the presentation slide deck is available on the
Company’s website.
https://www.immuron.com.au/corporate-presentations/
Approved for release by the
CEO.COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024